Balyasny Asset Management
ABBV icon

Balyasny Asset Management’s AbbVie ABBV Stock Holding History

Balyasny Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.28M Sell
19,700
-19,300
-49% -$4.28M 0.01% 1431
2025
Q4 		$8.91M Sell
39,000
-60,400
-61% -$13.8M 0.01% 1079
2025
Q3 		$23M Buy
99,400
+69,200
+229% +$14.1M 0.03% 657
2025
Q2 		$5.61M Sell
30,200
-90,900
-75% -$16.9M 0.01% 1232
2025
Q1 		$25.4M Buy
121,100
+13,200
+12% +$2.57M 0.04% 506
2024
Q4 		$19.2M Buy
107,900
+8,600
+9% +$1.58M 0.03% 691
2024
Q3 		$19.6M Buy
99,300
+52,300
+111% +$9.76M 0.03% 638
2024
Q2 		$8.06M Sell
47,000
-10,900
-19% -$1.81M 0.01% 972
2024
Q1 		$10.5M Sell
57,900
-73,600
-56% -$12.7M 0.02% 901
2023
Q4 		$20.4M Buy
131,500
+11,800
+10% +$1.72M 0.04% 593
2023
Q3 		$17.8M Buy
+119,700
New +$17.6M 0.04% 616
2023
Q2 		– Sell
-59,500
Closed -$9.48M – 2215
2023
Q1 		$9.48M Sell
59,500
-50,000
-46% -$7.64M 0.02% 799
2022
Q4 		$17.7M Hold
109,500
– – 0.05% 533
2022
Q3 		$14.7M Sell
109,500
-123,000
-53% -$17.7M 0.05% 531
2022
Q2 		$35.6M Buy
232,500
+15,000
+7% +$2.29M 0.12% 243
2022
Q1 		$35.3M Buy
+217,500
New +$31.6M 0.11% 236
2021
Q3 		– Sell
-7,300
Closed -$822K – 1878
2021
Q2 		$822K Buy
+7,300
New +$822K ﹤0.01% 1375
2019
Q3 		– Sell
-30,000
Closed -$2.36M – 1113
2019
Q2 		$2.36M Buy
+30,000
New +$2.36M 0.02% 828
2018
Q4 		– Sell
-57,000
Closed -$5.19M – 1346
2018
Q3 		$5.19M Buy
+57,000
New +$5.41M 0.02% 687
2016
Q4 		– Sell
-128,292
Closed -$86K – 1328
2016
Q3 		$86K Buy
+128,292
New +$8.31M ﹤0.01% 929
2015
Q1 		– Sell
-350,000
Closed -$22.9M – 922
2014
Q4 		$22.9M Buy
+350,000
New +$22.1M 0.21% 137

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management's ABBV Position: Q1 2026 in Review

Balyasny Asset Management reduced its AbbVie (ABBV) stake by 25% in Q1 2026, selling an estimated $2.66M and leaving 35,130 shares worth $7.64M. The position accounts for 0.01% of the portfolio, ranked #1156.

Balyasny Asset Management first reported a position in ABBV in Q2 2013 and has held it in 40 quarters since. The position peaked at $240M in Q2 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Balyasny Asset Management held 35,130 shares of AbbVie worth $7.64M as of Q1 2026.
  • Balyasny Asset Management sold 11,973 AbbVie shares in Q1 2026, an estimated $2.66M.
  • AbbVie made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1156 holding.
  • Balyasny Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 40 quarters since.
  • Balyasny Asset Management's AbbVie position peaked at $240M in Q2 2025.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.